^
    Back
    Association details:
    Biomarker:MAPK1 D321N
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:erlotinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Nature
    Title:

    Erlotinib sensitivity of MAPK1p.D321N mutation in head and neck squamous cell carcinoma

    Published date:
    04/20/2020
    Excerpt:
    ...we identified two MAPK1 mutations in recurrent HNSCC, MAPK1p.D321N, and p.R135K....Importantly, for MAPK1p.D321N mutant tumors, erlotinib treatment resulted in a significant reduction in tumor volume (60.3% reduction vs. vehicle treatment, P = 0.0037; Fig. 2a)…
    DOI:
    10.1038/s41525-020-0124-5